| __timestamp | Arrowhead Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 50829000 |
| Thursday, January 1, 2015 | 34718089 | 57305000 |
| Friday, January 1, 2016 | 40998209 | 116145000 |
| Sunday, January 1, 2017 | 32022880 | 159362000 |
| Monday, January 1, 2018 | 19110051 | 206366000 |
| Tuesday, January 1, 2019 | 26556257 | 228244000 |
| Wednesday, January 1, 2020 | 52275890 | 293355000 |
| Friday, January 1, 2021 | 80981000 | 401715000 |
| Saturday, January 1, 2022 | 124431000 | 459856000 |
| Sunday, January 1, 2023 | 90932000 | 542705000 |
| Monday, January 1, 2024 | 98761000 | 492128000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Exelixis, Inc. has consistently outpaced Arrowhead Pharmaceuticals, Inc. in SG&A spending, peaking in 2023 with a staggering 542% increase from its 2014 levels. In contrast, Arrowhead Pharmaceuticals, Inc. saw a more modest rise, with a 304% increase over the same period. This disparity highlights Exelixis, Inc.'s aggressive investment in administrative and sales functions, potentially signaling a robust growth strategy. However, the absence of data for Exelixis, Inc. in 2024 leaves room for speculation. As these companies navigate the competitive biotech landscape, their SG&A trends offer valuable insights into their strategic priorities and market positioning.
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
Dr. Reddy's Laboratories Limited and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Comparing Revenue Performance: Exelixis, Inc. or Arrowhead Pharmaceuticals, Inc.?
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Novavax, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.